Kratom faces scrutiny over health risks
Watch CBS News
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.
Similar Posts
At-home health test maker Thorne explores sale | Reuters News Agency
Business & FinanceDealsHealth 21 July 2023, 6:41 pm 1 minute Reuters exclusively reported that Thorne HealthTech Inc (THRN.O), a provider of at-home health tests and nutritional supplements, is exploring a sale. Market Impact Thorne’s shares ended trading on Friday up 12.9% at $5.95 on the news, giving the company a market value of $320 million….
Most patients using weight-loss drugs like Wegovy stop within a year, data show | Reuters News Agency
Health 11 July 2023, 5:39 pm 1 minute Reuters exclusively reported that Only about one-third of patients prescribed a popular weight-loss drug like Novo Nordisk’s (NOVOb.CO) Wegovy were still taking it a year later, while total healthcare costs for the group rose sharply. Market Impact Shares of the Danish drugmaker fell 2.3% on Tuesday. Article…
Catalent’s Indiana plant to make Novo’s Wegovy weight-loss drug | Reuters News Agency
Health 25 August 2023, 6:39 pm 1 minute Reuters exclusively reported that Novo Nordisk has hired Thermo Fisher as its second contract manufacturer for its hugely popular weight-loss drug Wegovy. Novo Chief Financial Officer Karsten Munk Knudsen told Reuters in May the company had signed up a second contract manufacturer in the United States, but…
YouTube taps hospitals to create videos to help people witnessing an overdose or heart attack
People walk past a billboard advertisement for YouTube in Berlin, Germany, on Sept. 27, 2019. Sean Gallup | Getty Images YouTube is taking steps to fight against medical misinformation, especially when it comes to finding immediate tips on how to handle an emergency. The company on Wednesday introduced a feature called First Aid Information Shelves,…
Celine Dion’s Sister Gives Heart-Wrenching Update On Singer’s Health Battle
At HuffPost, we believe that everyone needs high-quality journalism, but we understand that not everyone can afford to pay for expensive news subscriptions. That is why we are committed to providing deeply reported, carefully fact-checked news that is freely accessible to everyone. Our News, Politics and Culture teams invest time and care working on hard-hitting…
Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. As these new therapies begin treating patients, some investors see better times ahead next year. “We’ve seen a lot of innovation,” Dan Lyons, portfolio manager on the health-care team at Janus Henderson, said, explaining that he is bullish on 2024 because…
